Organization
K-Group Beta
7 clinical trials
Clinical trial
A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2026-08-21
Clinical trial
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory OsteosarcomaStatus: Active (not recruiting), Estimated PCD: 2023-08-30
Clinical trial
A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid TumorsStatus: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib in Subjects With Platinum-Resistant Ovarian CancerStatus: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube CancerStatus: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous CarcinomaStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)Status: Recruiting, Estimated PCD: 2025-04-30